{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:39:51Z","timestamp":1791841191959,"version":"4.3.4"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40257-026-01038-x","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:34:58Z","timestamp":1778733298000},"page":"725-744","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dermatologic Toxicities Induced by JAK Inhibitors"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4029-941X","authenticated-orcid":false,"given":"Luca","family":"Rapparini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Starace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Apalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"El Barch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Delpuech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Baali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"1038_CR1","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","volume":"13","author":"C Samuel","year":"2023","unstructured":"Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb). 2023;13:729\u201349. https:\/\/doi.org\/10.1007\/s13555-023-00892-5.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1038_CR2","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76:736\u201344. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.005.","journal-title":"J Am Acad Dermatol"},{"key":"1038_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, Bonelli M, Gadina M, O\u2019Shea JJ. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25\u201336. https:\/\/doi.org\/10.1038\/nrrheum.2015.167.","journal-title":"Nat Rev Rheumatol"},{"key":"1038_CR4","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303\u201311. https:\/\/doi.org\/10.1016\/S0140-6736(19)30419-2.","journal-title":"Lancet"},{"key":"1038_CR5","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D Van Der Heijde","year":"2019","unstructured":"Van Der Heijde D, Song I-H, Pangan AL, Deodhar A, Van Den Bosch F, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet. 2019;394:2108\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(19)32534-6.","journal-title":"Lancet"},{"key":"1038_CR6","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D\u2019Haens G, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease. Gastroenterology. 2020;158:2123-8.e8. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.047.","journal-title":"Gastroenterology"},{"key":"1038_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002838","volume":"10","author":"G Levy","year":"2022","unstructured":"Levy G, Guglielmelli P, Langmuir P, Constantinescu SN. JAK inhibitors and COVID-19. J Immunother Cancer. 2022;10:e002838. https:\/\/doi.org\/10.1136\/jitc-2021-002838.","journal-title":"J Immunother Cancer"},{"key":"1038_CR8","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","volume":"384","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384:1227\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2022516.","journal-title":"N Engl J Med"},{"key":"1038_CR9","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s10067-023-06529-4","volume":"42","author":"F Yang","year":"2023","unstructured":"Yang F, Lu C, Wang Y, Liu H, Leng X, Zeng X. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2023;42:1593\u2013605. https:\/\/doi.org\/10.1007\/s10067-023-06529-4.","journal-title":"Clin Rheumatol"},{"key":"1038_CR10","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158:1554-73.e12. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.001.","journal-title":"Gastroenterology"},{"key":"1038_CR11","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","volume":"91","author":"B King","year":"2024","unstructured":"King B, Senna MM, Mesinkovska NA, Lynde C, Zirwas M, Maari C, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91:880\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2024.06.097.","journal-title":"J Am Acad Dermatol"},{"key":"1038_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","volume":"25","author":"B King","year":"2024","unstructured":"King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, et al. Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program. Am J Clin Dermatol. 2024;25:299\u2013314. https:\/\/doi.org\/10.1007\/s40257-024-00846-3.","journal-title":"Am J Clin Dermatol"},{"key":"1038_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","volume":"24","author":"O Kwon","year":"2023","unstructured":"Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin C-Y, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24:443\u201351. https:\/\/doi.org\/10.1007\/s40257-023-00764-w.","journal-title":"Am J Clin Dermatol"},{"key":"1038_CR14","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/jamadermatol.2023.0391","volume":"159","author":"AS Paller","year":"2023","unstructured":"Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the Measure Up 1, Measure Up 2, and AD Up randomized clinical trials. JAMA Dermatol. 2023;159:526. https:\/\/doi.org\/10.1001\/jamadermatol.2023.0391.","journal-title":"JAMA Dermatol"},{"key":"1038_CR15","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, De Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397:2169\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(21)00589-4.","journal-title":"Lancet"},{"key":"1038_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamadermatol.2020.3095","volume":"157","author":"C Li","year":"2021","unstructured":"Li C, Li Z, Cao Y, Li L, Li F, Li Y, et al. Tofacitinib for the treatment of nail lesions and palmoplantar pustulosis in synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome. JAMA Dermatol. 2021;157:74. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3095.","journal-title":"JAMA Dermatol"},{"key":"1038_CR17","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387:1445\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2118828.","journal-title":"N Engl J Med"},{"key":"1038_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40257-022-00701-3","volume":"23","author":"SB Elmariah","year":"2022","unstructured":"Elmariah SB, Smith JS, Merola JF. JAK in the [black] box: a dermatology perspective on systemic JAK inhibitor safety. Am J Clin Dermatol. 2022;23:427\u201331. https:\/\/doi.org\/10.1007\/s40257-022-00701-3.","journal-title":"Am J Clin Dermatol"},{"key":"1038_CR19","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:1333. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3260.","journal-title":"JAMA Dermatol"},{"key":"1038_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70067","author":"BM Piraccini","year":"2025","unstructured":"Piraccini BM, Cedirian S, Pampaloni F, Rapparini L, Quadrelli F, Bruni F, et al. Effectiveness and safety of baricitinib in severe alopecia areata: 48\u2010week results. Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.70067.","journal-title":"Acad Dermatol Venereol"},{"key":"1038_CR21","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/jdv.20312","volume":"39","author":"BM Piraccini","year":"2025","unstructured":"Piraccini BM, Pampaloni F, Cedirian S, Quadrelli F, Bruni F, Rapparini L, et al. Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: a 24-week Italian study. J Eur Acad Dermatol Venereol. 2025;39:1143\u201351. https:\/\/doi.org\/10.1111\/jdv.20312.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1038_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40261-026-01533-3","volume":"46","author":"M Starace","year":"2026","unstructured":"Starace M, Pampaloni F, Quadrelli F, Olivoni G, Cedirian S, Rapparini L, et al. Effectiveness of baricitinib on nail alopecia areata: a 48-week single-center retrospective study. Clin Drug Investig. 2026;46(4):447\u201353. https:\/\/doi.org\/10.1007\/s40261-026-01533-3.","journal-title":"Clin Drug Investig"},{"key":"1038_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/jdv.15937","volume":"34","author":"L Guo","year":"2020","unstructured":"Guo L, Feng S, Sun B, Jiang X, Liu Y. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta\u2010analysis. Acad Dermatol Venereol. 2020;34:192\u2013201. https:\/\/doi.org\/10.1111\/jdv.15937.","journal-title":"Acad Dermatol Venereol"},{"key":"1038_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19090","author":"A Sechi","year":"2024","unstructured":"Sechi A, Song J, Dell\u2019Antonia M, Heidemeyer K, Piraccini BM, Starace M, et al. Adverse events in patients treated with Jak-inhibitors for alopecia areata: a systematic review. J Eur Acad Dermatol Venereol. 2024. https:\/\/doi.org\/10.1111\/jdv.19090. (Online ahead of print).","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1038_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jdv.19426","volume":"38","author":"S Yoon","year":"2024","unstructured":"Yoon S, Kim K, Shin K, Kim H-S, Kim B, Kim M-B, et al. The safety of systemic janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2024;38:52\u201361. https:\/\/doi.org\/10.1111\/jdv.19426.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1038_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396:255\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(20)30732-7.","journal-title":"Lancet"},{"issue":"3","key":"1038_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40257-025-00997-x","volume":"26","author":"ATM R\u00f8nnstad","year":"2025","unstructured":"R\u00f8nnstad ATM, Isufi D, Bunick CG, Chovatiya R, Nielsen M-L, Alinaghi F, et al. Real-world evidence of effectiveness and safety of abrocitinib, baricitinib and uadacitinib in atopic dermatitis: a systematic review and meta-analysis. Am J Clin Dermatol. 2025;26(3):411\u201324. https:\/\/doi.org\/10.1007\/s40257-025-00997-x.","journal-title":"Am J Clin Dermatol"},{"key":"1038_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03578-w","volume":"317","author":"O Lamberg","year":"2024","unstructured":"Lamberg O, Pandher K, Troost JP, Lim HW. Long-term adverse event risks of oral JAK inhibitors versus immunomodulators: a literature review. Arch Dermatol Res. 2024;317:109. https:\/\/doi.org\/10.1007\/s00403-024-03578-w.","journal-title":"Arch Dermatol Res"},{"key":"1038_CR29","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383:1511\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2008250.","journal-title":"N Engl J Med"},{"key":"1038_CR30","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus","year":"2023","unstructured":"Loftus EV, Pan\u00e9s J, Lacerda AP, Peyrin-Biroulet L, D\u2019Haens G, Panaccione R, et al. Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2023;388:1966\u201380. https:\/\/doi.org\/10.1056\/NEJMoa2212728.","journal-title":"N Engl J Med"},{"key":"1038_CR31","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397:2151\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(21)00588-2.","journal-title":"Lancet"},{"key":"1038_CR32","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386:1687\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2110343.","journal-title":"N Engl J Med"},{"key":"1038_CR33","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652\u201362. https:\/\/doi.org\/10.1056\/NEJMoa1608345.","journal-title":"N Engl J Med"},{"key":"1038_CR34","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand EF, Vital EM, Petri M, van Vollenhoven R, Wallace DJ, Mosca M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023;401:1001\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(22)02607-1.","journal-title":"Lancet"},{"key":"1038_CR35","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri M, Bruce IN, D\u00f6rner T, Tanaka Y, Morand EF, Kalunian KC, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023;401:1011\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(22)02546-6.","journal-title":"Lancet"},{"key":"1038_CR36","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","volume":"402","author":"AV Ramanan","year":"2023","unstructured":"Ramanan AV, Quartier P, Okamoto N, Foeldvari I, Spindler A, Fingerhutov\u00e1 \u0160, et al. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet. 2023;402:555\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(23)00921-2.","journal-title":"Lancet"},{"key":"1038_CR37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","volume":"85","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Forman S, Silverberg JI, Zirwas M, Maverakis E, Han G, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol. 2021;85:62\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2021.02.028.","journal-title":"J Am Acad Dermatol"},{"key":"1038_CR38","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, Tha\u00e7i D, Paul C, Pink AE, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384:1101\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2019380.","journal-title":"N Engl J Med"},{"key":"1038_CR39","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86:104\u201312. https:\/\/doi.org\/10.1016\/j.jaad.2021.05.075.","journal-title":"J Am Acad Dermatol"},{"key":"1038_CR40","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400:273\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(22)01199-0.","journal-title":"Lancet"},{"key":"1038_CR41","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(25)01576-4","volume":"406","author":"LS Gold","year":"2025","unstructured":"Gold LS, Armstrong AW, Bissonnette R, Magnolo N, Vender RB, Sebastian M, et al. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025;406:1363\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(25)01576-4.","journal-title":"Lancet"},{"key":"1038_CR42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88:40\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2022.08.061.","journal-title":"J Am Acad Dermatol"},{"key":"1038_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Tha\u00e7i D, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88:29\u201339. https:\/\/doi.org\/10.1016\/j.jaad.2022.07.002.","journal-title":"J Am Acad Dermatol"},{"key":"1038_CR44","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/bcp.70042","volume":"91","author":"C-H Shen","year":"2025","unstructured":"Shen C-H, Wang T-Y, Chi C-C. Janus kinase inhibitors for the treatment of lichen sclerosus: a systematic review. Br J Clin Pharmacol. 2025;91:1322\u20139. https:\/\/doi.org\/10.1002\/bcp.70042.","journal-title":"Br J Clin Pharmacol"},{"key":"1038_CR45","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40257-025-00979-z","volume":"26","author":"M Moshkovich","year":"2025","unstructured":"Moshkovich M, Andrade LF, Anderson M, Yosipovitch G. Lichen simplex chronicus: clinical perspectives and emerging therapeutic strategies. Am J Clin Dermatol. 2025;26:895\u2013903. https:\/\/doi.org\/10.1007\/s40257-025-00979-z.","journal-title":"Am J Clin Dermatol"},{"key":"1038_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40257-024-00912-w","volume":"26","author":"AG Messenger","year":"2025","unstructured":"Messenger AG, Asfour L, Harries M. Frontal fibrosing alopecia: an update. Am J Clin Dermatol. 2025;26:155\u201374. https:\/\/doi.org\/10.1007\/s40257-024-00912-w.","journal-title":"Am J Clin Dermatol"},{"key":"1038_CR47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40257-021-00636-1","volume":"23","author":"TP Joshi","year":"2022","unstructured":"Joshi TP, Duvic M. Granuloma annulare: an updated review of epidemiology, pathogenesis, and treatment options. Am J Clin Dermatol. 2022;23:37\u201350. https:\/\/doi.org\/10.1007\/s40257-021-00636-1.","journal-title":"Am J Clin Dermatol"},{"key":"1038_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104344","volume":"30","author":"M Malekan","year":"2025","unstructured":"Malekan M, Taghiloo S, Kazeminejad A, Gholizadeh N, Montazer F, Rokni GR. JAK inhibitors as a promising therapy for immune-mediated photodermatoses. Drug Discov Today. 2025;30:104344. https:\/\/doi.org\/10.1016\/j.drudis.2025.104344.","journal-title":"Drug Discov Today"},{"key":"1038_CR49","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40257-025-00946-8","volume":"26","author":"M Iorizzo","year":"2025","unstructured":"Iorizzo M, Sechi A, Neubauer ZJK, Zhou M, Lipner SR. JAK inhibitors and inflammatory nail disorders: a systematic review of clinical outcomes and therapeutic potential. Am J Clin Dermatol. 2025;26:525\u201336. https:\/\/doi.org\/10.1007\/s40257-025-00946-8.","journal-title":"Am J Clin Dermatol"},{"key":"1038_CR50","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40261-026-01533-3","volume":"46","author":"M Starace","year":"2026","unstructured":"Starace M, Pampaloni F, Quadrelli F, Olivoni G, Cedirian S, Rapparini L, et al. Effectiveness of baricitinib on nail alopecia areata: a 48-week single-center retrospective study. Clin Drug Investig. 2026;46:447\u201353. https:\/\/doi.org\/10.1007\/s40261-026-01533-3.","journal-title":"Clin Drug Investig"},{"key":"1038_CR51","doi-asserted-by":"publisher","first-page":"354","DOI":"10.55563\/clinexprheumatol\/eeglsa","volume":"43","author":"JJ Paik","year":"2025","unstructured":"Paik JJ, Vencovsk\u00fd J, Charles-Schoeman C, Wright GC, Vleugels RA, Goriounova AS, et al. Brepocitinib, a potent and selective TYK2\/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis. Clin Exp Rheumatol. 2025;43:354\u201363. https:\/\/doi.org\/10.55563\/clinexprheumatol\/eeglsa.","journal-title":"Clin Exp Rheumatol"},{"key":"1038_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/exd.70095","volume":"34","author":"M Spadafora","year":"2025","unstructured":"Spadafora M, Morsia S, Di Lernia VG, Kaleci S, Pellacani G, Longo C. Off-label use of topical ruxolitinib in dermatology: a systematic literature review and current perspectives. Exp Dermatol. 2025;34:e70095. https:\/\/doi.org\/10.1111\/exd.70095.","journal-title":"Exp Dermatol"},{"key":"1038_CR53","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40257-022-00752-6","volume":"24","author":"KN Cunningham","year":"2023","unstructured":"Cunningham KN, Rosmarin D. Vitiligo treatments: review of current therapeutic modalities and JAK inhibitors. Am J Clin Dermatol. 2023;24:165\u201386. https:\/\/doi.org\/10.1007\/s40257-022-00752-6.","journal-title":"Am J Clin Dermatol"},{"key":"1038_CR54","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van Den Bosch F, Kivitz A, Bessette L, Li Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:2503\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(18)31115-2.","journal-title":"Lancet"},{"key":"1038_CR55","doi-asserted-by":"publisher","first-page":"E31","DOI":"10.1002\/ajh.26398","volume":"97","author":"M Moutel","year":"2022","unstructured":"Moutel M, Noel V, Jary A, Le Q-H, Lier C, Viguier M, et al. Iatrogenic Kaposi\u2019s sarcoma in a myelofibrosis patient treated with ruxolitinib: case-report, literature review, and French pharmacovigilance data. Am J Hematol. 2022;97:E31\u20134. https:\/\/doi.org\/10.1002\/ajh.26398.","journal-title":"Am J Hematol"},{"key":"1038_CR56","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/jdv.18922","volume":"37","author":"DN Adam","year":"2023","unstructured":"Adam DN, Gooderham MJ, Beecker JR, Hong CH, Jack CS, Jain V, et al. Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol. 2023;37:1135\u201348. https:\/\/doi.org\/10.1111\/jdv.18922.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1038_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.70152","volume":"6","author":"A Blanco-S\u00e1nchez","year":"2025","unstructured":"Blanco-S\u00e1nchez A, Ayala R, Carre\u00f1o-Tarragona G, Colmenares R, L\u00f3pez-Mu\u00f1oz N, S\u00e1ez A, et al. Long-term safety profile of ruxolitinib in chronic myeloproliferative neoplasms: a comprehensive real-world analysis. EJHaem. 2025;6:e70152. https:\/\/doi.org\/10.1002\/jha2.70152.","journal-title":"EJHaem"},{"key":"1038_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16111960","volume":"16","author":"M Starace","year":"2024","unstructured":"Starace M, Rapparini L, Cedirian S. Skin malignancies due to anti-cancer therapies. Cancers (Basel). 2024;16:1960. https:\/\/doi.org\/10.3390\/cancers16111960.","journal-title":"Cancers (Basel)"},{"key":"1038_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17111795","volume":"17","author":"F Bernardi","year":"2025","unstructured":"Bernardi F, Faggiani I, Parigi TL, Zilli A, Allocca M, Furfaro F, et al. JAK inhibitors and risk of cancer in IBD patients. Cancers (Basel). 2025;17:1795. https:\/\/doi.org\/10.3390\/cancers17111795.","journal-title":"Cancers (Basel)"},{"key":"1038_CR60","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1136\/ard-2023-224049","volume":"82","author":"MD Russell","year":"2023","unstructured":"Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis. 2023;82:1059\u201367. https:\/\/doi.org\/10.1136\/ard-2023-224049.","journal-title":"Ann Rheum Dis"},{"key":"1038_CR61","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/bjd\/ljae342","volume":"192","author":"C Haag","year":"2024","unstructured":"Haag C, Alexis A, Aoki V, Bissonnette R, Blauvelt A, Chovatiya R, et al. A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council. Br J Dermatol. 2024;192:135\u201343. https:\/\/doi.org\/10.1093\/bjd\/ljae342.","journal-title":"Br J Dermatol"},{"key":"1038_CR62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503531","author":"RA Vleugels","year":"2026","unstructured":"Vleugels RA, Paik JJ, Bauer Ventura I, Mangold AR, Gandiga PC, Haemel A, et al. A phase 3 trial of brepocitinib in dermatomyositis. N Engl J Med. 2026. https:\/\/doi.org\/10.1056\/NEJMoa2503531. (Online ahead of print).","journal-title":"N Engl J Med"},{"key":"1038_CR63","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jaad.2024.01.004","volume":"90","author":"G Avallone","year":"2024","unstructured":"Avallone G, Mastorino L, Tavoletti G, Macagno N, Barei F, Schena D, et al. Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: a multicenter retrospective study. J Am Acad Dermatol. 2024;90:1031\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2024.01.004.","journal-title":"J Am Acad Dermatol"},{"key":"1038_CR64","doi-asserted-by":"publisher","first-page":"125","DOI":"10.14309\/ajg.0000000000003119","volume":"120","author":"MJ Temido","year":"2025","unstructured":"Temido MJ, Honap S, Bursztejn AC, Portela F, Jairath V, Danese S, et al. Drug-induced acne in inflammatory bowel disease: a practical guide for the gastroenterologist. Am J Gastroenterol. 2025;120:125\u201334. https:\/\/doi.org\/10.14309\/ajg.0000000000003119.","journal-title":"Am J Gastroenterol"},{"key":"1038_CR65","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15688","volume":"35","author":"C Correia","year":"2022","unstructured":"Correia C, Antunes J, Filipe P. Management of acne induced by JAK inhibitors. Dermatol Ther. 2022;35:e15688. https:\/\/doi.org\/10.1111\/dth.15688.","journal-title":"Dermatol Ther"},{"key":"1038_CR66","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-026-01022-5","author":"M Starace","year":"2026","unstructured":"Starace M, Rapparini L, Pampaloni F, Cedirian S, Quadrelli F, Bruni F, et al. Ritlecitinib for severe alopecia areata: a 24-week, multicentre, real-world study. Am J Clin Dermatol. 2026. https:\/\/doi.org\/10.1007\/s40257-026-01022-5. (Online ahead of print).","journal-title":"Am J Clin Dermatol"},{"key":"1038_CR67","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.5443","author":"MC Schneeweiss","year":"2026","unstructured":"Schneeweiss MC, Wyss R, Anand P, Jin Y, Mostaghimi A, Barbieri J, et al. Risk of acne in patients with atopic dermatitis starting a JAK inhibitor vs Th2 cytokine inhibitor. JAMA Dermatol. 2026. https:\/\/doi.org\/10.1001\/jamadermatol.2025.5443.","journal-title":"JAMA Dermatol"},{"key":"1038_CR68","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/jamadermatol.2023.3830","volume":"159","author":"J Martinez","year":"2023","unstructured":"Martinez J, Manjaly C, Manjaly P, Ly S, Zhou G, Barbieri J, et al. Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis. JAMA Dermatol. 2023;159:1339\u201345. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3830.","journal-title":"JAMA Dermatol"},{"key":"1038_CR69","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2397477","volume":"35","author":"B-L Chen","year":"2024","unstructured":"Chen B-L, Huang S, Dong X-W, Wu D-D, Bai Y-P, Chen Y-Y. Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis. J Dermatolog Treat. 2024;35:2397477. https:\/\/doi.org\/10.1080\/09546634.2024.2397477.","journal-title":"J Dermatolog Treat"},{"key":"1038_CR70","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00011-023-01789-x","volume":"72","author":"C Sun","year":"2023","unstructured":"Sun C, Su Z, Zeng Y-P. Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis. Inflamm Res. 2023;72:1861\u201371. https:\/\/doi.org\/10.1007\/s00011-023-01789-x.","journal-title":"Inflamm Res"},{"key":"1038_CR71","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s13555-023-00961-9","volume":"13","author":"N Hayashi","year":"2023","unstructured":"Hayashi N, Ikeda M, Liu J, Raymundo E, Liu Y, Sasaki T, et al. Acne among Japanese patients with atopic dermatitis receiving upadacitinib in the phase 3 Rising Up Study. Dermatol Ther (Heidelb). 2023;13:1817\u201330. https:\/\/doi.org\/10.1007\/s13555-023-00961-9.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1038_CR72","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.cgh.2025.04.031","volume":"24","author":"S Honap","year":"2026","unstructured":"Honap S, Temido MJ, Shakweh E, Badrulhisham F, Shields N, Mehta S, et al. Janus kinase (JAK) inhibitor-induced acne in inflammatory bowel disease: an international, multicenter, retrospective cohort study. Clin Gastroenterol Hepatol. 2026;24(2):484\u201392. https:\/\/doi.org\/10.1016\/j.cgh.2025.04.031.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1038_CR73","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jaad.2022.06.012","volume":"87","author":"P Mendes-Bastos","year":"2022","unstructured":"Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022;87:784\u201391. https:\/\/doi.org\/10.1016\/j.jaad.2022.06.012.","journal-title":"J Am Acad Dermatol"},{"key":"1038_CR74","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1093\/ibd\/izaf115","volume":"31","author":"D Choi","year":"2025","unstructured":"Choi D, Kellar A, Klein J, Choi NK, Garcia NM, Friedberg S, et al. Incidence and risk factors for development of acne (JAKne) in patients with inflammatory bowel disease treated with upadacitinib. Inflamm Bowel Dis. 2025;31:2311\u20134. https:\/\/doi.org\/10.1093\/ibd\/izaf115.","journal-title":"Inflamm Bowel Dis"},{"key":"1038_CR75","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jdcr.2022.09.029","volume":"30","author":"S-D Lee","year":"2022","unstructured":"Lee S-D, Ahn H-J, Shin MK. A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis. JAAD Case Rep. 2022;30:11\u20136. https:\/\/doi.org\/10.1016\/j.jdcr.2022.09.029.","journal-title":"JAAD Case Rep"},{"key":"1038_CR76","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.11657","volume":"103","author":"F Ballanger","year":"2023","unstructured":"Ballanger F, Auffret N, Leccia M-T, Claudel JP, Dr\u00e9no B. Acneiform lesions but not acne after treatment with Janus kinase inhibitors: diagnosis and management of Janus kinase-acne. Acta Derm Venereol. 2023;103:adv11657. https:\/\/doi.org\/10.2340\/actadv.v103.11657.","journal-title":"Acta Derm Venereol"},{"key":"1038_CR77","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1111\/ijd.17435","volume":"63","author":"J Huang","year":"2024","unstructured":"Huang J, Ji R, Li J, Guo Y, Shi W. Characterization and clinical outcomes of JAK inhibitor-associated acne (JAK-acne) in patients with alopecia areata treated with tofacitinib: a single-center retrospective study. Int J Dermatol. 2024;63:e350\u20132. https:\/\/doi.org\/10.1111\/ijd.17435.","journal-title":"Int J Dermatol"},{"key":"1038_CR78","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jaad.2025.09.026","volume":"94","author":"PV Warp","year":"2026","unstructured":"Warp PV, Garrett G, Aggarwal R, Maderal AD, Elman SA. Real-world characteristics of Janus kinase inhibitor-associated acne: a 14-year retrospective cohort study. J Am Acad Dermatol. 2026;94:306\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2025.09.026.","journal-title":"J Am Acad Dermatol"},{"key":"1038_CR79","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/jdv.18027","volume":"36","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Nymand LK, Maul J-T, Schmid-Grendelmeier P, Wu JJ, Thomsen SF, et al. Incidence, prevalence and risk of acne in adolescent and adult patients with atopic dermatitis: a matched cohort study. J Eur Acad Dermatol Venereol. 2022;36:890\u20136. https:\/\/doi.org\/10.1111\/jdv.18027.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1038_CR80","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/jdv.20674","volume":"39","author":"LF van der Gang","year":"2025","unstructured":"van der Gang LF, Atash K, Zuithoff NPA, Haeck I, Boesjes CM, Baco\u015f-Cosma OI, et al. Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results. J Eur Acad Dermatol Venereol. 2025;39:2056\u201368. https:\/\/doi.org\/10.1111\/jdv.20674.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1038_CR81","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s13555-024-01203-2","volume":"14","author":"M Mansilla-Polo","year":"2024","unstructured":"Mansilla-Polo M, Morgado-Carrasco D. Biologics versus JAK inhibitors. Part II: risk of infections. A narrative review. Dermatol Ther (Heidelb). 2024;14:1983\u20132038. https:\/\/doi.org\/10.1007\/s13555-024-01203-2.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1038_CR82","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58:1755\u201366. https:\/\/doi.org\/10.1093\/rheumatology\/kez087.","journal-title":"Rheumatology (Oxford)"},{"key":"1038_CR83","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1080\/14740338.2024.2348571","volume":"23","author":"G Caldarola","year":"2024","unstructured":"Caldarola G, Pinto LM, Bellinato F, Bernardini N, Campione E, Chiricozzi A, et al. Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment. Expert Opin Drug Saf. 2024;23:1483\u20137. https:\/\/doi.org\/10.1080\/14740338.2024.2348571.","journal-title":"Expert Opin Drug Saf"},{"key":"1038_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152120","volume":"58","author":"K Winthrop","year":"2023","unstructured":"Winthrop K, Isaacs J, Calabrese L, Mittal D, Desai S, Barry J, et al. Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: a structured literature review. Semin Arthritis Rheum. 2023;58:152120. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152120.","journal-title":"Semin Arthritis Rheum"},{"key":"1038_CR85","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.reumae.2021.06.001","volume":"18","author":"CO S\u00e1nchez Gonz\u00e1lez","year":"2022","unstructured":"S\u00e1nchez Gonz\u00e1lez CO, Nieto Gonz\u00e1lez JC. JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis: systematic review of the literature. Reumatolog\u00eda Cl\u00ednica (English Edition). 2022;18:453\u20138. https:\/\/doi.org\/10.1016\/j.reumae.2021.06.001.","journal-title":"Reumatolog\u00eda Cl\u00ednica (English Edition)"},{"key":"1038_CR86","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.cgh.2025.07.028","volume":"24","author":"R Panaccione","year":"2026","unstructured":"Panaccione R, Regueiro M, Lee SD, Atreya R, Pedersen G, Broide E, et al. Upadacitinib maintenance therapy in Crohn\u2019s disease: final results from the randomized phase 3 U-ENDURE study. Clin Gastroenterol Hepatol. 2026;24:772\u201383. https:\/\/doi.org\/10.1016\/j.cgh.2025.07.028.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1038_CR87","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2109927.","journal-title":"N Engl J Med"},{"key":"1038_CR88","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","volume":"25","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, Winthrop K, Guttman-Yassky E, Hoffmeister KM, et al. Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4 years of exposure. Am J Clin Dermatol. 2024;25:639\u201354. https:\/\/doi.org\/10.1007\/s40257-024-00869-w.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1038_CR89","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/jdv.70172","volume":"40","author":"CG Bunick","year":"2026","unstructured":"Bunick CG, Irvine AD, Silverberg JI, Guttman-Yassky E, Shahriari M, Gao X, et al. Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6\u2009years. J Eur Acad Dermatol Venereol. 2026;40(5):856\u201366. https:\/\/doi.org\/10.1111\/jdv.70172.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1038_CR90","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/jdv.18193","volume":"36","author":"T Werfel","year":"2022","unstructured":"Werfel T, Irvine AD, Bangert C, Seneschal J, Grond S, Cardillo T, et al. An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2022;36:1486\u201396. https:\/\/doi.org\/10.1111\/jdv.18193.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1038_CR91","doi-asserted-by":"publisher","first-page":"195","DOI":"10.14309\/ajg.0000000000001510","volume":"117","author":"C Steenholdt","year":"2022","unstructured":"Steenholdt C, Kristensen LE, Brynskov J. Herpes zoster meningoencephalitis: a novel, rare, potentially fatal side effect to tofacitinib. Am J Gastroenterol. 2022;117:195\u20136. https:\/\/doi.org\/10.14309\/ajg.0000000000001510.","journal-title":"Am J Gastroenterol"},{"key":"1038_CR92","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1111\/jdv.19483","volume":"38","author":"N Abu Rached","year":"2024","unstructured":"Abu Rached N, Gambichler T, Ocker L, Schultheis B, Susok L, Schmidt W, et al. Upadacitinib treatment associated with varicella zoster infection complicated by haemophagocytic lymphohistiocytosis in a patient with severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2024;38:e139\u201341. https:\/\/doi.org\/10.1111\/jdv.19483.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1038_CR93","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-090668","volume":"14","author":"S Takanashi","year":"2024","unstructured":"Takanashi S, Ohmura K, Misaki K, Ihata A, Matsui T, Tohma S, et al. Optimal timing of recombinant herpes zoster virus vaccination for a JAK inhibitor treatment in rheumatoid arthritis: a multicentre, open-label, randomised comparative study (STOP-HZ study): study protocol. BMJ Open. 2024;14:e090668. https:\/\/doi.org\/10.1136\/bmjopen-2024-090668.","journal-title":"BMJ Open"},{"key":"1038_CR94","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1093\/ibd\/izy150","volume":"24","author":"J-F Colombel","year":"2018","unstructured":"Colombel J-F. Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention. Inflamm Bowel Dis. 2018;24:2173\u201382. https:\/\/doi.org\/10.1093\/ibd\/izy150.","journal-title":"Inflamm Bowel Dis"},{"key":"1038_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/v14020192","volume":"14","author":"A Patil","year":"2022","unstructured":"Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. Viruses. 2022;14:192. https:\/\/doi.org\/10.3390\/v14020192.","journal-title":"Viruses"},{"key":"1038_CR96","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12016-016-8548-5","volume":"51","author":"PY Ong","year":"2016","unstructured":"Ong PY, Leung DYM. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev Allergy Immunol. 2016;51:329\u201337. https:\/\/doi.org\/10.1007\/s12016-016-8548-5.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1038_CR97","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/jdv.16948","volume":"35","author":"T Bieber","year":"2021","unstructured":"Bieber T, Thyssen JP, Reich K, Simpson EL, Katoh N, Torrelo A, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35:476\u201385. https:\/\/doi.org\/10.1111\/jdv.16948.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1038_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-019-08768-3","volume":"59","author":"A Damour","year":"2020","unstructured":"Damour A, Garcia M, Seneschal J, L\u00e9v\u00eaque N, Bodet C. Eczema herpeticum: clinical and pathophysiological aspects. Clinic Rev Allerg Immunol. 2020;59:1\u201318. https:\/\/doi.org\/10.1007\/s12016-019-08768-3.","journal-title":"Clinic Rev Allerg Immunol"},{"key":"1038_CR99","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1111\/ajd.13059","volume":"60","author":"GN Wong","year":"2019","unstructured":"Wong GN, Lee S, Foley P. A case of widespread molluscum contagiosum caused by baricitinib, a Janus kinase inhibitor. Australas J Dermatol. 2019;60:e334\u20135. https:\/\/doi.org\/10.1111\/ajd.13059.","journal-title":"Australas J Dermatol"},{"key":"1038_CR100","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/1346-8138.13404","volume":"43","author":"M Kinoshita","year":"2016","unstructured":"Kinoshita M, Ogawa Y, Kawamura T, Kirito K, Shimada S. Case of disseminated molluscum contagiosum caused by ruxolitinib, a Janus kinase 1 and 2 inhibitor. J Dermatol. 2016;43:1387\u20138. https:\/\/doi.org\/10.1111\/1346-8138.13404.","journal-title":"J Dermatol"},{"key":"1038_CR101","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1080\/09546634.2022.2104445","volume":"33","author":"E De Luca","year":"2022","unstructured":"De Luca E, Gori N, Chiricozzi A, Di Stefani A, Peris K. Periocular molluscum contagiosum in an atopic dermatitis patient treated with upadacitinib. J Dermatolog Treat. 2022;33:3068\u20139. https:\/\/doi.org\/10.1080\/09546634.2022.2104445.","journal-title":"J Dermatolog Treat"},{"key":"1038_CR102","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.3899\/jrheum.200730","volume":"48","author":"VJ Gilvaz","year":"2021","unstructured":"Gilvaz VJ, Mody E, Abaalkhail S. A case of disseminated cutaneous Mycobacterium chelonae infection during treatment with tofacitinib. J Rheumatol. 2021;48:1623. https:\/\/doi.org\/10.3899\/jrheum.200730.","journal-title":"J Rheumatol"},{"key":"1038_CR103","doi-asserted-by":"publisher","DOI":"10.5070\/D331265289","author":"SA Valek","year":"2025","unstructured":"Valek SA, Black TA, Aboul-Fettouh N, Rogge MN. An atypical mycobacterial infection while on Janus kinase inhibitor therapy. Dermatol Online J. 2025. https:\/\/doi.org\/10.5070\/D331265289.","journal-title":"Dermatol Online J"},{"key":"1038_CR104","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1093\/rheumatology\/keac710","volume":"62","author":"L Meudec","year":"2023","unstructured":"Meudec L, Richeb\u00e9 P, Pascaud J, Mariette X, Nocturne G. Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity. Rheumatology (Oxford). 2023;62:2855\u201363. https:\/\/doi.org\/10.1093\/rheumatology\/keac710.","journal-title":"Rheumatology (Oxford)"},{"key":"1038_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023;8:204. https:\/\/doi.org\/10.1038\/s41392-023-01468-7.","journal-title":"Signal Transduct Target Ther"},{"key":"1038_CR106","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1111\/jdv.20809","volume":"39","author":"KA Papp","year":"2025","unstructured":"Papp KA, Puig L, Beecker J, Chandran V, Claveau J, Cort\u00e9s J, et al. Systemic treatment of immune checkpoint inhibitor-induced psoriasis: inference-based guidance. J Eur Acad Dermatol Venereol. 2025;39:1881\u201394. https:\/\/doi.org\/10.1111\/jdv.20809.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1038_CR107","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf1329","volume":"384","author":"D Mathew","year":"2024","unstructured":"Mathew D, Marmarelis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science. 2024;384:eadf1329. https:\/\/doi.org\/10.1126\/science.adf1329.","journal-title":"Science"},{"key":"1038_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103649","volume":"23","author":"C Ramakrishna","year":"2024","unstructured":"Ramakrishna C, Mason A, Edwards CJ. Tyrosine kinase 2 inhibitors in autoimmune diseases. Autoimmun Rev. 2024;23:103649. https:\/\/doi.org\/10.1016\/j.autrev.2024.103649.","journal-title":"Autoimmun Rev"},{"key":"1038_CR109","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jaad.2022.11.043","volume":"88","author":"MA Kreher","year":"2023","unstructured":"Kreher MA, Konda S, Noland MMB, Longo MI, Valdes-Rodriguez R. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors. J Am Acad Dermatol. 2023;88:534\u201342. https:\/\/doi.org\/10.1016\/j.jaad.2022.11.043.","journal-title":"J Am Acad Dermatol"},{"key":"1038_CR110","doi-asserted-by":"publisher","unstructured":"Rapparini L, Touhouche TA, Fattore D, Freites-Martinez A, Hirtz P, Apalla Z, et al. Corrective and restorative dermatology in cancer survivors: an urgent unmet need! Am J Clin Dermatol. 2026. https:\/\/doi.org\/10.1007\/s40257-026-01027-0(Online ahead of print).","DOI":"10.1007\/s40257-026-01027-0"},{"key":"1038_CR111","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2340\/00015555-2181","volume":"96","author":"CA Harwood","year":"2016","unstructured":"Harwood CA, Proby CM, Inman GJ, Leigh IM. The promise of genomics and the development of targeted therapies for cutaneous squamous cell carcinoma. Acta Derm Venereol. 2016;96:3\u201316. https:\/\/doi.org\/10.2340\/00015555-2181.","journal-title":"Acta Derm Venereol"},{"key":"1038_CR112","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991\u20138. https:\/\/doi.org\/10.1038\/ni1102-991.","journal-title":"Nat Immunol"},{"key":"1038_CR113","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","volume":"161","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Lebwohl M, Warren RB, Sofen H, Imafuku S, Ohtsuki M, et al. Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3 years: an open-label extension of randomized clinical trials. JAMA Dermatol. 2025;161:56\u201366. https:\/\/doi.org\/10.1001\/jamadermatol.2024.4688.","journal-title":"JAMA Dermatol"},{"key":"1038_CR114","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40257-022-00720-0","volume":"23","author":"AM L\u00e9","year":"2022","unstructured":"L\u00e9 AM, Puig L, Torres T. Deucravacitinib for the treatment of psoriatic disease. Am J Clin Dermatol. 2022;23:813\u201322. https:\/\/doi.org\/10.1007\/s40257-022-00720-0.","journal-title":"Am J Clin Dermatol"},{"key":"1038_CR115","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00815-y","volume":"22","author":"CS Greif","year":"2021","unstructured":"Greif CS, Srivastava D, Nijhawan RI. Janus kinase inhibitors and non-melanoma skin cancer. Curr Treat Options Oncol. 2021;22:11. https:\/\/doi.org\/10.1007\/s11864-020-00815-y.","journal-title":"Curr Treat Options Oncol"},{"key":"1038_CR116","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1136\/ard-2022-222543","volume":"82","author":"JR Curtis","year":"2023","unstructured":"Curtis JR, Yamaoka K, Chen Y-H, Bhatt DL, Gunay LM, Sugiyama N, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023;82:331\u201343. https:\/\/doi.org\/10.1136\/ard-2022-222543.","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"1038_CR117","doi-asserted-by":"publisher","first-page":"02959","DOI":"10.1016\/j.jaad.2025.10.011","volume":"S0190\u20139622","author":"V Shah","year":"2025","unstructured":"Shah V, Nijhawan RI. Skin cancer risk in bone-marrow transplant patients treated with ruxolitinib compared with other immunosuppressive therapies. J Am Acad Dermatol. 2025;S0190\u20139622(25):02959\u201367. https:\/\/doi.org\/10.1016\/j.jaad.2025.10.011.","journal-title":"J Am Acad Dermatol"},{"key":"1038_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082197","volume":"15","author":"C Bezzio","year":"2023","unstructured":"Bezzio C, Vernero M, Ribaldone DG, Alimenti E, Manes G, Saibeni S. Cancer risk in patients treated with the JAK inhibitor tofacitinib: systematic review and meta-analysis. Cancers (Basel). 2023;15:2197. https:\/\/doi.org\/10.3390\/cancers15082197.","journal-title":"Cancers (Basel)"},{"key":"1038_CR119","doi-asserted-by":"publisher","unstructured":"Wollenberg A, Ikeda M, Chu C-Y, Eichenfield LF, Seyger MMB, Prakash A, et al. Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years. J Dermatol Treat. 2024;35:2411834. https:\/\/doi.org\/10.1080\/09546634.2024.2411834.","DOI":"10.1080\/09546634.2024.2411834"},{"key":"1038_CR120","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","volume":"158","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Papp KA, Blauvelt A, Chu C-Y, Hong HC-H, Katoh N, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol. 2022;158:404\u201313. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0029.","journal-title":"JAMA Dermatol"},{"key":"1038_CR121","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jaad.2021.10.004","volume":"86","author":"JQ Lin","year":"2022","unstructured":"Lin JQ, Li SQ, Li S, Kiamanesh EF, Aasi SZ, Kwong BY, et al. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with Polycythemia Vera and myelofibrosis. J Am Acad Dermatol. 2022;86:339\u201344. https:\/\/doi.org\/10.1016\/j.jaad.2021.10.004.","journal-title":"J Am Acad Dermatol"},{"key":"1038_CR122","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s00277-021-04647-0","volume":"100","author":"R Sekhri","year":"2021","unstructured":"Sekhri R, Sadjadian P, Becker T, Kolatzki V, Huenerbein K, Meixner R, et al. Ruxolitinib-treated Polycythemia Vera patients and their risk of secondary malignancies. Ann Hematol. 2021;100:2707\u201316. https:\/\/doi.org\/10.1007\/s00277-021-04647-0.","journal-title":"Ann Hematol"},{"key":"1038_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10:55. https:\/\/doi.org\/10.1186\/s13045-017-0417-z.","journal-title":"J Hematol Oncol"},{"key":"1038_CR124","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/blood.2023022345","volume":"143","author":"A Rampotas","year":"2024","unstructured":"Rampotas A, Carter-Brzezinski L, Somervaille TCP, Forryan J, Panitsas F, Harrison C, et al. Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib. Blood. 2024;143:178\u201382. https:\/\/doi.org\/10.1182\/blood.2023022345.","journal-title":"Blood"},{"key":"1038_CR125","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.annder.2020.10.018","volume":"148","author":"M Sauvage","year":"2021","unstructured":"Sauvage M, Tavitian S, Sibaud V, Boulinguez S, Pages-Laurent C, Lamant L, et al. Aggressive locoregional behavior of cutaneous squamous cell carcinoma during ruxolitinib use. Ann Dermatol Venereol. 2021;148:140\u20131. https:\/\/doi.org\/10.1016\/j.annder.2020.10.018.","journal-title":"Ann Dermatol Venereol"},{"key":"1038_CR126","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1111\/ijd.17371","volume":"63","author":"M Mansilla-Polo","year":"2024","unstructured":"Mansilla-Polo M, L\u00f3pez-Davia J, De Unamuno-Bustos B, Mart\u00edn-Torregrosa D, Abril-P\u00e9rez C, Ezzatvar Y, et al. Skin cancer risk after hematopoietic stem cell transplantation: a systematic review and meta-analysis. Int J Dermatol. 2024;63:1691\u2013700. https:\/\/doi.org\/10.1111\/ijd.17371.","journal-title":"Int J Dermatol"},{"key":"1038_CR127","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1056\/NEJMc2304157","volume":"389","author":"GH Lee","year":"2023","unstructured":"Lee GH, Guzman AK, Divito SJ, Soiffer RJ, Silk AW, Schmults CD. Cutaneous squamous-cell carcinoma after treatment with ruxolitinib or belumosudil. N Engl J Med. 2023;389:188\u201390. https:\/\/doi.org\/10.1056\/NEJMc2304157.","journal-title":"N Engl J Med"},{"key":"1038_CR128","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1111\/1346-8138.15259","volume":"47","author":"T Omine","year":"2020","unstructured":"Omine T, Yamaguchi S, Yasumura R, Asakura Y, Takahashi K. Iatrogenic Kaposi\u2019s sarcoma in a myelofibrosis patient treated with ruxolitinib. J Dermatol. 2020;47:e131\u20132. https:\/\/doi.org\/10.1111\/1346-8138.15259.","journal-title":"J Dermatol"},{"key":"1038_CR129","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jdcr.2023.07.019","volume":"39","author":"C Fournier","year":"2023","unstructured":"Fournier C, Sauder MB, Kamil ZS, Butler MO. Kaposi sarcoma in a patient treated with upadacitinib for rheumatoid arthritis. JAAD Case Rep. 2023;39:145\u20139. https:\/\/doi.org\/10.1016\/j.jdcr.2023.07.019.","journal-title":"JAAD Case Rep."},{"key":"1038_CR130","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000678","volume":"8","author":"P Wetwittayakhlang","year":"2021","unstructured":"Wetwittayakhlang P, Golovics PA, Afif W, Bessissow T, Lakatos PL. Tofacitinib-associated iatrogenic Kaposi sarcoma in a patient with ulcerative colitis. ACG Case Rep J. 2021;8:e00678. https:\/\/doi.org\/10.14309\/crj.0000000000000678.","journal-title":"ACG Case Rep J."},{"key":"1038_CR131","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","volume":"88","author":"K Papp","year":"2023","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Forman SB, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. J Am Acad Dermatol. 2023;88:1008\u201316. https:\/\/doi.org\/10.1016\/j.jaad.2022.09.060.","journal-title":"J Am Acad Dermatol"},{"key":"1038_CR132","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaad.2025.05.1385","volume":"93","author":"LF Eichenfield","year":"2025","unstructured":"Eichenfield LF, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, et al. Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: results from TRuE-AD3, a phase 3, randomized double-blind study. J Am Acad Dermatol. 2025;93:689\u201398. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1385.","journal-title":"J Am Acad Dermatol"},{"key":"1038_CR133","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40257-023-00840-1","volume":"25","author":"W Hu","year":"2024","unstructured":"Hu W, Thornton M, Livingston RA. Real-world use of ruxolitinib cream: safety analysis at 1 year. Am J Clin Dermatol. 2024;25:327\u201332. https:\/\/doi.org\/10.1007\/s40257-023-00840-1.","journal-title":"Am J Clin Dermatol"},{"key":"1038_CR134","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jaad.2025.06.058","volume":"93","author":"K Benandi","year":"2025","unstructured":"Benandi K, Spires A, Hansen A, Linfante A. Systemic risk profiles of topical ruxolitinib and oral Janus kinase inhibitors in patients with atopic dermatitis: a retrospective cohort study from the TriNetX network. J Am Acad Dermatol. 2025;93:1035\u201341. https:\/\/doi.org\/10.1016\/j.jaad.2025.06.058.","journal-title":"J Am Acad Dermatol"},{"key":"1038_CR135","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1111\/jdv.19162","volume":"37","author":"G Tavoletti","year":"2023","unstructured":"Tavoletti G, Avallone G, Conforti C, Roccuzzo G, Maronese CA, Mattioli MA, et al. Topical ruxolitinib: a new treatment for vitiligo. J Eur Acad Dermatol Venereol. 2023;37:2222\u201330. https:\/\/doi.org\/10.1111\/jdv.19162.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1038_CR136","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41409-023-02181-3","volume":"59","author":"Z Hudda","year":"2024","unstructured":"Hudda Z, Flannery A, Teusink-Cross A, Davies SM, Khandelwal P. Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD. Bone Marrow Transplant. 2024;59:425\u20137. https:\/\/doi.org\/10.1038\/s41409-023-02181-3.","journal-title":"Bone Marrow Transplant"},{"key":"1038_CR137","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1111\/jdv.20379","volume":"39","author":"K Ezzedine","year":"2025","unstructured":"Ezzedine K, Wolkerstorfer A, Wei S, Korba AA, Kornacki D, Rosmarin D. Incidence of nonmelanoma skin cancer in patients with vitiligo who applied ruxolitinib cream. J Eur Acad Dermatol Venereol. 2025;39:e378\u201380. https:\/\/doi.org\/10.1111\/jdv.20379.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1038_CR138","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","volume":"404","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024;404:461\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(24)01027-4.","journal-title":"Lancet"},{"key":"1038_CR139","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/S0140-6736(25)00001-7","volume":"405","author":"AM Gim\u00e9nez-Arnau","year":"2025","unstructured":"Gim\u00e9nez-Arnau AM, Pinter A, Sondermann W, Reguiai Z, Woolf R, Lynde C, et al. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial. Lancet. 2025;405:1676\u201388. https:\/\/doi.org\/10.1016\/S0140-6736(25)00001-7.","journal-title":"Lancet"},{"key":"1038_CR140","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2021.06.014","volume":"85","author":"H Nakagawa","year":"2021","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kabashima K, Oda M, et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol. 2021;85:854\u201362. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.014.","journal-title":"J Am Acad Dermatol"},{"key":"1038_CR141","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/ijd.15853","volume":"61","author":"H Wood","year":"2022","unstructured":"Wood H, Chandler A, Nezamololama N, Papp K, Gooderham MJ. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. Int J Dermatol. 2022;61:746\u201354. https:\/\/doi.org\/10.1111\/ijd.15853.","journal-title":"Int J Dermatol"},{"key":"1038_CR142","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","volume":"148","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148:927\u201340. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.009.","journal-title":"J Allergy Clin Immunol"},{"key":"1038_CR143","unstructured":"Alys Pharmaceuticals. Alys Pharmaceuticals announces dosing of first patient in phase IIa trial of ALY-101 for alopecia areata. 2025. https:\/\/alyspharma.com\/alys-pharmaceuticals-announces-dosing-of-first-patient-in-phase-iia-trial-of-aly-101-for-alopecia-areata\/. Accessed 21 Apr 2026."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01038-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01038-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01038-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:21:58Z","timestamp":1784186518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01038-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":143,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1038"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01038-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"8 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Open access funding provided by Alma Mater Studiorum\u2014Universit\u00e0 di Bologna within the CRUI-CARE Agreement. No external funding was used in the preparation of this article.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Luca Rapparini, Michela Starace, Zoe Apalla, Maha El Barch, Antoine Delpuech, Sarah Baali, and Vincent Sibaud have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patients, or patient\u2019s parents\/guardians, in this article have given written informed consent to the publication of their photos, according to the Declaration of Helsinki principles.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No datasets were generated or analyzed during the current study. A review of the literature was conducted using previously published data.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the conception and drafting of the manuscript and provided clinical images. All authors critically revised the manuscript for important intellectual content and approved the final version of the manuscript.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}